TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04742842

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: COVIGEN C19 2.0 mg IM or Placebo IM
Description: 2 doses of COVIGEN C19 2.0 mg IM or Placebo IM will be given at Day 1 and Day 29.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: COVIGEN C19 4.0 mg IM or Placebo IM
Description: 2 doses of COVIGEN C19 4.0 mg IM or Placebo IM will be given at Day 1 and Day 29.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: COVIGEN C20 1.0mg vaccine ID
Description: COVIGEN C20 1.0mg ID vaccine will be given at Day 1

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: COVIGEN C20 1.0mg vaccine ID
Description: COVIGEN C20 1.0mg ID vaccine will be given at Day 1
Study: NCT04673851

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Horyzons USA
Description: Participants will be oriented to the site (online platform) and how to use it. The site includes curated therapeutic content surrounding issues such as generalized anxiety, social anxiety, social functioning, depression, and distress tolerance. The site also includes a social media function, in which participants and peer support specialists can post text, images, and videos. The site is monitored by graduate students and trained clinicians.

Intervention type: DEVICE
Group type: OTHER
Intervention: Horyzons USA
Description: Participants will be oriented to the site (online platform) and how to use it. The site includes curated therapeutic content surrounding issues such as generalized anxiety, social anxiety, social functioning, depression, and distress tolerance. The site also includes a social media function, in which participants and peer support specialists can post text, images, and videos. The site is monitored by graduate students and trained clinicians.
Study: NCT06146855

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Tunneling procedure with De-epithelialized Free Gingival Graft
Description: Root Coverage by tunneling procedure with the addition of De-epithelialized Free Gingival Graft
Study: NCT05709769

Intervention type: OTHER
Intervention: There are no interventions.
Description: There are no interventions.

Intervention type: OTHER
Intervention: There are no interventions.
Description: There are no interventions.
Study: NCT04851561

Intervention type: DIAGNOSTIC_TEST
Intervention: Cardiopulmonary stress test (CPET)
Description: Cardiopulmonary stress test will be conducted under the guidance of sports and exercise physicians and nursing staff. Electrocardiogram, spirometry, blood pressure and gas exchange measuring will be assessed at rest. The participants will then undergo CPET according to a modified Astrand treadmill test protocol. The test will be terminated at maximal exercise or upon the appearance of limiting symptoms. Continuous electrocardiogram and repeated blood pressure measuring will be conducted at the recovery phase. Post-exercise spirometry will also be assessed.

Intervention type: DIAGNOSTIC_TEST
Intervention: Cardiopulmonary stress test (CPET)
Description: Cardiopulmonary stress test will be conducted under the guidance of sports and exercise physicians and nursing staff. Electrocardiogram, spirometry, blood pressure and gas exchange measuring will be assessed at rest. The participants will then undergo CPET according to a modified Astrand treadmill test protocol. The test will be terminated at maximal exercise or upon the appearance of limiting symptoms. Continuous electrocardiogram and repeated blood pressure measuring will be conducted at the recovery phase. Post-exercise spirometry will also be assessed.
Study: NCT05433389

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Breath Counting
Description: Patients will listen to a 5-minute, audio-recorded breath counting practice.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Body Scan
Description: Patients will listen to a 5-minute, audio-recorded body scan practice.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindful Breathing
Description: Patients will listen to a 5-minute, audio-recorded mindful breathing practice.
Study: NCT06111937

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: after ultrasound gastric assessment to ensure gastric empty, painless colonoscopy was performed within 2 hours
Description: Patients received gastric ultrasound examination every 15 minutes 2 or 4 hours immediately after taking the last dose of MgSO4 solution in group A or B respectively.
Study: NCT05433389

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindfulness of Pain
Description: Patients will listen to a 5-minute, audio-recorded mindfulness of pain practice.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindful Savoring
Description: Patients will listen to a 5-minute, audio-recorded mindful savoring practice.
Study: NCT06523452

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laser Speckle Imaging
Description: At least three scans (four for skin sparing mastectomy) will be performed on participants randomised to the LSI Assisted Group. Further scans may be taken at the discretion of the surgeon.
Study: NCT06473155

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Experimental: Humanistic Integrative Psychotherapy and Identity Exploration (HIP+EYME)
Description: Eight weekly, one-hour sessions based on HIP (including techniques such as analyzing transactions, recognizing ego states, script analysis, letter to my future self --10 years from now, psychoeducation on emotional intelligence, chair work with subpersonalities, fearful scene work, imaginal work with the life project) and the immersive exploration of personal identity using EYME.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Experimental: Humanistic Integrative Psychotherapy, Identity, and Geniotype Exploration (HIP+EYME+GENIOTYPE)
Description: Eight weekly, one-hour sessions based on HIP (including techniques such as analyzing transactions, recognizing ego states, script analysis, letter to my future self --10 years from now, psychoeducation on emotional intelligence, chair work with subpersonalities, fearful scene work, imaginal work with the life project) and the immersive exploration of personal identity using EYME. Also, participants will answer the Geniotype questionnaire and the results will be worked with the adolescents.
Study: NCT05878808

Intervention type: DIAGNOSTIC_TEST
Intervention: Psychometric assessment
Description: Eighty subjects diagnosed with bipolar I disorder were enrolled in this study, subjects were divided according to the presence or absence of OCD to Group A: Bipolar disorder patients with OCD (n = 26), Group B: Bipolar disorder patients without OCD (n = 54). The following scales were applied: Dimensional Yale-Brown obsessive compulsive scale (DYBOCS)- Beck scale for Suicidal ideations (BSSI) - Hamilton depression rating scale (HDRS) and Young mania rating scale (YMRS).

Intervention type: DIAGNOSTIC_TEST
Intervention: Psychometric assessment
Description: Eighty subjects diagnosed with bipolar I disorder were enrolled in this study, subjects were divided according to the presence or absence of OCD to Group A: Bipolar disorder patients with OCD (n = 26), Group B: Bipolar disorder patients without OCD (n = 54). The following scales were applied: Dimensional Yale-Brown obsessive compulsive scale (DYBOCS)- Beck scale for Suicidal ideations (BSSI) - Hamilton depression rating scale (HDRS) and Young mania rating scale (YMRS).
Study: NCT05913934

Intervention type: BEHAVIORAL
Intervention: Gait analysis
Description: Walk over 25 meters in a gym (GaitUp) Walk over 6 meters with footscan v9 in the office
Study: NCT05962814

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: EarGenie MVP test
Description: The EarGenie test consists of placing the EarGenie headgear on the infant and running the fNIRS tests via the user interface. Blocks of speech sounds are presented to the infant via earphones or via speaker, and the EarGenie MVP measures changes in the blood oxygenation. Automatic analyses are run to determine whether the infant heard the sounds or discriminated between them. The infant will be in a natural sleep when the fNIRS test is run. Prior to the test, standard audiometric procedures (otoscopy and tympanometry) will confirm normal middle ear function.
Study: NCT05509205

Intervention type: OTHER
Intervention: Turkish Validity and Reliability of The PSS Scale
Description: This study is about validation of the Pound Satisfaction Scale to Turkish. The level of satisfaction with the rehabilitation service and treatment of 130 stroke patients undergoing stroke rehabilitation will be evaluated with the Pound satisfaction scale.
Study: NCT05464446

Intervention type: DEVICE
Intervention: Baseline Bubble Inclinometer, Baseline Digital İnclinometer and Hoggan microFET2 devices
Description: Bubble inclinometer was used to measure lumbar lordosis angle, Digital inclinometer was used to measure pelvic inclination angle and Hoggan microFET2 was used for muscle strength measurement.
Study: NCT04828434

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Virtual Individual Cognitive Simulation Therapy
Description: Virtual Individual Cognitive Stimulation Therapy (V-iCST) is an individual and virtual adaptation of Cognitive Stimulation Therapy (CST), a routine psychosocial treatment for people with mild to moderate dementia in the UK.
Study: NCT06368141

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Serplulimab
Description: Participants will receive a pre-operative CAPEOX and a sequential CAPEOX plus Serplulimab regimen.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capecitabine
Description: Participants will receive a pre-operative CAPEOX and a sequential CAPEOX plus Serplulimab regimen.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxaliplatin
Description: Participants will receive a pre-operative CAPEOX and a sequential CAPEOX plus Serplulimab regimen.
Study: NCT05784012

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dostarlimab
Description: Dostarlimab 500 mg IV every 21 days in neoadjuvant and adjuvant stage.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dostarlimab
Description: Dostarlimab 500 mg IV every 21 days in neoadjuvant and adjuvant stage.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Niraparib
Description: Niraparib 200 or 300mg orally administered QD in neoadjuvant, concurrent with radiotherapy and adjuvant stage until completing week 48.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cisplatin plus radiotherapy
Description: In the concurrent phase

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Niraparib
Description: Niraparib 200 or 300mg orally administered QD (Neoadjuvant and Maintenance stages).
Study: NCT05104060

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: pectoralis minor intervention group
Description: The subjects in pectoralis minor group will received manual therapy for pectoralis minor by physical therapist, the technique including stretch and soft tissue mobilization. The subjects asked to perform the scapular control exercise and shoulder strength exercise.Subjects will be correct scapular resting position and then do elevation in scapular plane.Four exercises for shoulder strength will do shoulder flexion, abduction, internal and external rotation with thera-band.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: shoulder strengthening group
Description: The subjects in the scapular strengthening group will be asked to do four exercises for shoulder strength, including shoulder flexion, abduction, internal and external rotation with thera-band.
Study: NCT05326737

Intervention type: OTHER
Intervention: In hospital pain evaluation
Description: Patients will evaluate their pain levels via a verbal numerical scale on days 1(or-1), 2, 3, 4, 5, 6 \& 7.

Intervention type: OTHER
Intervention: In hospital questionnaires
Description: Patients are required to fill out the PCS questionnaire between on day -1 or +1.

Intervention type: OTHER
Intervention: Telephone contact at 3 months
Description: Patients will be contacted at 3 months post-surgery for pain questionnaires DN4 and EQ5D5L.
Study: NCT04811521

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Primary care follow-up
Description: Those randomized to primary care and enhanced primary care coordination will receive the minimal intensity treatment that includes: (1) assistance in identifying a primary care provider for participants who do not have one, (2) sharing results of diagnostic testing (including anxiety screening) with the primary care provider (results sent via EMR note, mailed letter, or delivered by participant at appointment); and (3) an educational brochure on anxiety and treatment.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Online Self-Administered Anxiety Management Program plus Peer Support Guidance
Description: Individuals randomized to the online Cognitive Behavioral Therapy (CBT) + peer support guidance arm will receive access to six online, evidence-based CBT modules in the This Way Up Generalized Anxiety Course to be completed weekly or bi-monthly. Individuals who screen positive on the PHQ panic measure will complete 2 additional panic-specific homework assignments applying exposure therapy to panic (in addition to Generalized Anxiety Disorder) experiences aligned with content from the This Way Up Panic Course.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Therapist-Administered Cognitive Behavioral Therapy
Description: Individuals randomized to therapist-led CBT via telehealth will receive 8 one-hour sessions over the course of 8 to 10 weeks via telehealth (HIPAA compliant software such as Zoom Health or AmWell) or telephone. Therapists will be master's-degreed or eligible clinicians trained in CBT by our study psychologist. Therapists will follow a manualized protocol for delivering CBT for anxiety, specifically, with a primary focus on anxiety and worry management. Individuals who screen positive on the PHQ panic measure will have training in exposure therapy added to CBT. Although many CBT trials have a standard length of 12 sessions, brief CBT lasting 4-8 sessions is equally efficacious.
Study: NCT06448312

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SKB264
Description: IV Infusion

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pembrolizumab
Description: IV Infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: IV Infusion
Study: NCT06241599

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GP/PFLL+AK104
Description: Groups 1 and 2: Patients who have not been treated with PFLL in front-line therapy. 5-Fu:200mg/m2/d, d1-30, continuous intravenous infusion; Cisplatin: 80mg/m2, intravenous infusion for 4h, the first and 28th days of each cycle; AK104: 6mg/kg intravenous infusion for more than 60 minutes, used on days 1, 15, 30, 45 of each cycle, and administered 30 minutes before chemotherapy drugs during chemotherapy.~Groups 3 and 4: Patients who had never used GP in their front-line treatment regimen. Gemcitabine: 1000mg/m2, used on the 1st and 8th day of each cycle; Cisplatin: 80mg/m2 on the first day of each cycle; AK104 6mg/kg intravenous infusion for more than 60 minutes was used on day 1, 15 (single cycle)/or day 8 (double cycle) of each cycle, and was administered 30 minutes before chemotherapy drugs during chemotherapy. Every 3 weeks is a treatment cycle, with a maximum of 6 cycles used. After 6 cycles of chemotherapy, both groups could continue to receive AK104 (once every 2 weeks).

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: GP/PFLL+placebo
Description: Groups 1 and 2: Patients who have not been treated with PFLL in front-line therapy. 5-Fu:200mg/m2/d, d1-30, continuous intravenous infusion; Cisplatin: 80mg/m2, intravenous infusion for 4h, the first and 28th days of each cycle; placebo: 6mg/kg intravenous infusion for more than 60 minutes, used on days 1, 15, 30, 45 of each cycle, and administered 30 minutes before chemotherapy drugs during chemotherapy.~Groups 3 and 4: Patients who had never used GP in their front-line treatment regimen. Gemcitabine: 1000mg/m2, used on the 1st and 8th day of each cycle; Cisplatin: 80mg/m2 on the first day of each cycle; placebo 6mg/kg intravenous infusion for more than 60 minutes was used on day 1, 15 (single cycle)/or day 8 (double cycle) of each cycle, and was administered 30 minutes before chemotherapy drugs during chemotherapy. Every 3 weeks is a treatment cycle, with a maximum of 6 cycles used. After 6 cycles of chemotherapy, both groups could continue to receive placebo (once every 2 weeks).
Study: NCT04980846

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Driving under the influence of alcohol with a driving simulator
Description: Participants will drive in three different states (sober, drunk above and below the legal limit) on designated circuits using a driving simulator. After the initial sober driving session, participants are administered pre-mixed alcoholic beverages (e.g., vodka orange). Participants are expected to achieve a target BrAC of 0.35 mg/l (legal limit in Switzerland is 0.25 mg/l BrAC) before the second driving session starts. Finally, the third driving session starts when the participants' BrAC drops to 0.15 mg/l. Heart rate, skin conductance, accelerometer, eye movement, radar, facial expression, and speech will be recorded by a smart-watch, an eye-tracker, microphones and an onboard camera, respectively.~Participants will be blinded to their alcohol levels during the study. They will have to rate their symptoms and their performance via questionnaires before and after each driving session. Further, capillary blood and oral fluid samples will be collected.
Study: NCT05892120

Intervention type: BEHAVIORAL
Intervention: the MedAdhere app
Description: The experimental group downloaded and used the MedAdhere app on their personal smartphones during this 8-week study
Study: NCT05623904

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Carotid Revascularization
Description: Carotid Artery Stenting/Carotid Endarterectomy

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Medical Treatment
Description: Aspirin 100mg/ day plus clopidogrel 75mg/ day for the first three months after enrollment or revascularization, aspirin 100mg/ day after three months, and the statin dose was adjusted according to blood lipids levels. Best medical treatment also includes risk factor control: good lifestyle, smoking cessation, weight control, regular exercise, SBP \< 140 mmHg, HDL \< 70 mg/dl (1.8mmol/L), and glycemic control. Patients with poor control of risk factors were dynamically adjusted during follow-up.~In addition, patients undergoing CAS received dual antiplatelet therapy for at least 3 to 5 days before surgery, and patients undergoing CEA also received a preoperative oral antiplatelet drug (aspirin 100mg/ day, or clopidogrel 75mg/ day) for at least 3 days after enrollment.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Medical Treatment
Description: Aspirin 100mg/ day plus clopidogrel 75mg/ day for the first three months after enrollment or revascularization, aspirin 100mg/ day after three months, and the statin dose was adjusted according to blood lipids levels. Best medical treatment also includes risk factor control: good lifestyle, smoking cessation, weight control, regular exercise, SBP \< 140 mmHg, HDL \< 70 mg/dl (1.8mmol/L), and glycemic control. Patients with poor control of risk factors were dynamically adjusted during follow-up.~In addition, patients undergoing CAS received dual antiplatelet therapy for at least 3 to 5 days before surgery, and patients undergoing CEA also received a preoperative oral antiplatelet drug (aspirin 100mg/ day, or clopidogrel 75mg/ day) for at least 3 days after enrollment.
Study: NCT06122428

Intervention type: DRUG
Intervention: modified hyaluronic acid 0.1% covalently linked to Riboflavin
Description: The patients used the eye drops no less than 3 times a day or no more than 6 times a day, according to their needs. They reported the instillation frequency (3/4 or 5/6 times per day) on the provided document

Intervention type: DRUG
Intervention: hyaluronic acid 0.1%
Description: The patients used the eye drops no less than 3 times a day or no more than 6 times a day, according to their needs. They reported the instillation frequency (3/4 or 5/6 times per day) on the provided document
Study: NCT04901065

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Xylocaine
Description: The study intervention was the administration of 10 mg of intranasal lidocaine in one nostril using 1 spray of 0.1mL of a 10% lidocaine solution 5 minutes before NPS. This was done using the standard long nozzle

Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: Placebo
Description: The control group received the placebo with the same application technique using an empty bottle of lidocaine 10% with the same long nozzle for delivery
Study: NCT04541212

Intervention type: DIAGNOSTIC_TEST
Intervention: Cardiac Imaging
Description: Cardiac Imaging: echography, ECG, MRI Blood tests: Lipid profile, hs-CRP, metabolic markers, HDL functionality, pharmacogenetic testing (optional), hematocrit, pregnancy test

Intervention type: DIAGNOSTIC_TEST
Intervention: Cardiac Imaging
Description: Cardiac Imaging: echography, ECG, MRI Blood tests: Lipid profile, hs-CRP, metabolic markers, HDL functionality, pharmacogenetic testing (optional), hematocrit, pregnancy test

Intervention type: OTHER
Intervention: Data Collection
Description: Collection of retrospective data
Study: NCT05495074

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: ATP III dietary intervention
Description: The dietary intervention will consist of an approximate decrease of 500 kcal from the calories participants habitually consume, with the following macronutrient distribution 15-20% protein, 50-60% carbohydrates, 25-35% fat. Participants will receive recipes with menus for two weeks.